Navigation Links
Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKline's Avandia Increases Nine-Fold Following Publication of Meta-Analysis

Nearly Three-Quarters of Physicians Have Switched Patients to Merck's

Januvia, According to a New Report from Decision Resources

WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the percentage of primary care physicians (PCPs) and endocrinologists who consider the cardiovascular safety of GlaxoSmithKline's Avandia to be a major concern increased more than nine-fold following publication of a meta-analysis. Published in May 2007 by Steve Nissen in the New England Journal of Medicine, the meta-analysis calls into question the cardiovascular safety of Avandia and features analysis of data from several different trials showing that the drug increases the risk of myocardial infarction by 43 percent. Prescriptions for Avandia dropped significantly in the weeks following publication of the meta-analysis. According to the new Physician and Payer Forum report entitled Avandia One Year Later-A Physician and Payer Perspective, the full impact of the meta-analysis on Avandia prescribing has not yet been felt. 58 percent of PCPs and 52 percent of endocrinologists say they will reduce their prescribing of Avandia over the next year.

The report also finds that nearly three-quarters of physicians say they have switched patients to Merck's Januvia as a result of the Avandia meta-analysis. More than 80 percent of surveyed physicians say they will increase the number of total prescriptions they write for Januvia over the next two years. Although clinicians and managed care organizations surveyed consider metformin (Bristol-Myers Squibb's Glucophage, generics) to offer the best overall safety and efficacy, Januvia received the second greatest number of votes for "agent with the best overall safety profile" and for "lowest risk of hypoglycemia." In comparison, Amylin/Eli Lilly's Byetta was chosen by endocrinologists and MCOs as the agent least likely to cause weight gain, and the drug also received the third greatest number of votes for "agent with the best overall efficacy profile."

"Cardiovascular safety concerns have significantly impacted prescriptions for Avandia and created opportunities for other antidiabetic agents," said Donny Wong, Ph.D., principal analyst at Decision Resources. "Nearly three-quarters of physicians say they have switched patients to Januvia as a result of the Avandia meta-analysis, and one-third of PCPs and endocrinologists say they have switched patients to Byetta following publication of the Avandia meta-analysis. Nevertheless, Takeda's Actos will continue to be the market share leader among oral antidiabetic agents until the drug loses patent protection in 2011."

Avandia One Year Later-A Physician and Payer Perspective is based on a U.S. survey of 74 PCPs, 70 endocrinologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wal-Mart & Nalgene Removing Toxic Bottles, Place Consumers Concerns First
2. 18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns
3. Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves
4. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
5. Iomai Reports Going Concern Qualification in 10-K
6. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
7. Talent Shortage Emerges as No. 1 Employer Concern: Deloitte/ISCEBS
8. National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health
9. Project Concern International Receives a US$1 Million Grant From the Starbucks Foundations Ethos Water Fund to Provide Safe Water and Sanitation Services in Tanzania
10. Bi-Partisan Members of United States Senate Formally Raise Concerns About Proposed Cuts to Medicares Home Oxygen Benefit
11. TransUnion Addresses Ohio Attorney Generals Concerns Surrounding Non-Profit Tax-Exempt Status
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology: